Cavisiran

N/A

Report date: 2024/05/15 15:12:44
NME

Base Information

Drug NameCavisiran
Drug Alias NameENB-101ENB101-LNP
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceProtein E7 inhibitorsProtein E6 inhibitors
TargetsProtein E7Protein E6
Therapy Area/IndicationsUterine Cervical NeoplasmsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEnhancedBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesEnhancedBio Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsHead and Neck Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A